BRAF and colorectal carcinoma: Furthermore, the information available from this report suggests that PD-L1 could be utilized as a prognostic marker in Middle Eastern CRC patients for risk stratification and that PD-1/PD-L1 inhibitors might be a valid therapeutic option for patients with advanced CRCs harboring BRAF mutation or showing deficient MMR.